# EDGAR Filing Document

**Accession Number:** 0001539029
**File Stem:** 0001193125-26-005412
**Filing Date:** 2026-1
**Character Count:** 2899
**Document Hash:** 3cfdcd13d3c48dbf3574cff6dff1f288
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-005412.hdr.sgml**: 20260107

**ACCESSION NUMBER**: 0001193125-26-005412

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260107

**DATE AS OF CHANGE**: 20260107

**EFFECTIVENESS DATE**: 20260107

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Clearside Biomedical, Inc.
- **CENTRAL INDEX KEY:** 0001539029
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 452437375
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37783
- **FILM NUMBER:** 26513933

**BUSINESS ADDRESS:**
- **STREET 1:** 900 NORTH POINT PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30005
- **BUSINESS PHONE:** 678-270-3631

**MAIL ADDRESS:**
- **STREET 1:** 900 NORTH POINT PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30005

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 15** 

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

**Commission File Number: 001-37783** 

## Clearside Biomedical, Inc.
**(Exact name of registrant as specified in its charter)** 

**900 North Point Parkway, Suite 200** 

**Alpharetta, Georgia 30005** 

**(678) 270-3631** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Common Stock, par value $0.001 per share** 

**(Title of each class of securities covered by this Form)** 

**None** 

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)** 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
|  Rule 12g-4(a)(1) | ☐ |
|  Rule 12g-4(a)(2) | ☐ |
|  Rule 12h-3(b)(1)(i) | ☐ |
|  Rule 12h-3(b)(1)(ii) | ☐ |
|  Rule 15d-6 | ☒ |
|  Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: Approximately 90.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Clearside Biomedical, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
|  | **CLEARSIDE BIOMEDICAL, INC.** | **CLEARSIDE BIOMEDICAL, INC.** |
| Date: January 7, 2026 | By: | /s/ Charles A. Deignan |
|  | Name: | Charles A. Deignan |
|  | Title: | Chief Financial Officer |

---